CSIMarket Company Name, Ticker, Industry, else..
 
Vbi Vaccines Inc  (NASDAQ: VBIV)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 25
 Employees 31
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -84
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Business Description


VBI Vaccines Inc. is a biotechnology company that develops and commercializes novel vaccines and immunotherapies for infectious diseases. The company's focus is on developing vaccines for preventing and treating diseases such as hepatitis B, cytomegalovirus, and glioblastoma. VBI Vaccines utilizes their proprietary enveloped virus-like particle (eVLP) platform technology to design and produce vaccines that offer enhanced immune responses. Their innovative approach aims to address unmet medical needs and improve global public health by providing effective and cost-efficient vaccines.


   Company Address: 160 Second Street Cambridge 2142 MA
   Company Phone Number: 830-3031   Stock Exchange / Ticker: NASDAQ VBIV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.83%    
EBS   -3.05%    
KYNB   -5.57%    
OPK   -4.97%    
PFE   -4.46%    
REGN   -7.13%    
• View Complete Report
   



Business Update

VBI Vaccines Provides an Update on its Restructuring Proceedings

Published Mon, Aug 5 2024 8:40 AM UTC

Strategic Restructuring and Legal Proceedings: VBI Vaccines Inc. s Current Landscape and Future Prospects The biotechnology sector is marked by rapid innovation and occasional turbulence, as evidenced by recent events at VBI Vaccines Inc. (Nasdaq: VBIV). VBI, a biopharmaceutical company committed to advancing immunology for disease prevention and treatment, is currently und...
Business Update

VBI Vaccines Inc. Updates on Restructuring Proceedings Under Chapter 15 Filing

Published Sun, Aug 4 2024 8:06 AM UTC

This article provides an in-depth examination of the recent restructuring proceedings of VBI Vaccines Inc. (Nasdaq: VBIV) as it navigates financial challenges and seeks to stabilize its operations. Following the initial announcement on July 30, 2024, the company has made significant strides in its restructuring efforts, including receiving provisional relief under Chapter 1...
Business Update

VBI Vaccines Navigates Financial Challenges Amidst Restructuring Efforts

Published Sat, Aug 3 2024 6:12 AM UTC

In a significant development within the biopharmaceutical sector, VBI Vaccines Inc. (NASDAQ: VBIV), known for its immunology-driven breakthroughs, has taken decisive steps to navigate financial headwinds as it implements a strategic restructuring. The company’s challenges and recent decisions underscore the turbulent landscape many biotech firms face in their quest for inn...
Business Update

VBI Vaccines Updates on Restructuring Proceedings, Reports Strong Shareholder Engagement and Promising Clinical...

Published Fri, Aug 2 2024 9:07 PM UTC

CAMBRIDGE, Mass. VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology and dedicated to pioneering solutions for the prevention and treatment of diseases, has recently provided important updates on its current restructuring proceedings, as well as significant insights into its ongoing clinical studies and shareholder engagement. Restructuring...
Business Update

VBI Vaccines Navigates Strategic Reconstruction Amid Promising New Data on Glioblastoma Immunotherapy

Published Tue, Jul 30 2024 7:47 PM UTC

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Facilitate Strategic Alternatives In a significant development for VBI Vaccines Inc. (Nasdaq: VBIV), a leading biopharmaceutical company focused on immunology and the advancement of therapeutic solutions, the Ontario Superior Court of Justice has granted the company protection under the Companies Creditors Arran...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.16
Working Capital Ratio 0.22
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -6.93 $
Revenues (TTM) 0.38 $
Cash Flow (TTM) -
Cash 0.51 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 303,581
Net Income per Employee (TTM) -2,709,355
Receivable Turnover Ratio (TTM) 57.12
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.14

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -968.04 %
Net Margin (MRQ) -1474.46 %
Net Cash Flow Margin (MRQ) -913.51 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.